Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(118 produits)
- EGFR(582 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2382 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52FGFR-IN-6
CAS :FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Formule :C23H22N6O3Couleur et forme :SolidMasse moléculaire :430.46EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Couleur et forme :SolidTyrphostin 63
CAS :Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183iBFAR2
CAS :iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33AZ-3
CAS :AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formule :C20H28FN7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :385.48Andamertinib
CAS :Andamertinib is an EGFR inhibitor with antitumor activity.Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669AFP464 free base
CAS :AFP464 (NSC710464) free base is an active HIF-1α inhibitor (IC50: 0.25 μM) and a potent aryl hydrocarbon receptor (AhR) activator.Formule :C22H23F3N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.44EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.97Bayer-18
CAS :Bayer-18 is an inhibitor of TYK2. It inhibits the viability of anaplastic large cell lymphoma cells, including K299, SR786, Mac1, and Mac2a, with an IC50 ranging from 2-3 µM. Additionally, Bayer-18 induces apoptosis in K299 and SR786 cells.Formule :C19H27FN6O2Couleur et forme :SolidMasse moléculaire :390.46EGFR-IN-139
CAS :EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951VEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Formule :C20H21N3O2Couleur et forme :SolidMasse moléculaire :335.4MM-589
CAS :MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formule :C28H44N8O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :572.70Lomonitinib
CAS :Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.Formule :C27H24N4O2Couleur et forme :SolidMasse moléculaire :436.505EGFR-IN-146
CAS :EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Formule :C20H16N4Couleur et forme :SolidMasse moléculaire :312.368MTX-216
CAS :MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Formule :C22H14Cl2FN5O2SCouleur et forme :SolidMasse moléculaire :502.348BMS-986143
CAS :BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formule :C31H24Cl2N4O4Couleur et forme :SolidMasse moléculaire :587.45JAK3/BTK-IN-4
CAS :JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formule :C21H25ClN8OCouleur et forme :SolidMasse moléculaire :440.93FLT3-IN-13
FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.Formule :C20H14N4O2Couleur et forme :SolidMasse moléculaire :342.35FLT3/ITD-IN-1
FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.Formule :C19H22N6O2Couleur et forme :SolidMasse moléculaire :366.42HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23BML-265
CAS :BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331VEGFR-2-IN-11
VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.Formule :C29H22BrN5SCouleur et forme :SolidMasse moléculaire :552.49ERBB agonist-1
CAS :ERBB agonist-1, ERBB4 agonist (EC50=10.5 μM), induces receptor dimerization/phosphorylation of Akt and ERK1/2, cardioprotective.Formule :C24H25N3O2SDegré de pureté :99.90%Couleur et forme :SolidMasse moléculaire :419.54Ref: TM-T204401
1mgÀ demander5mgÀ demander10mg124,00€25mg241,00€50mg358,00€100mgÀ demander1mL*10mM (DMSO)94,00€FAK-IN-26
CAS :FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.Formule :C20H19BrFN5O2Couleur et forme :SolidMasse moléculaire :460.30(-)-Cevimeline hydrochloride hemihydrate
(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.Formule :C10H19ClNO1·5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :244.78Tyk2-IN-3
CAS :Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formule :C25H24N6O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.63(3S,4R)-Tofacitinib
CAS :(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37Siphonaxanthin
CAS :Siphonaxanthin is a carotenoid found in green algae, known for targeting the death receptor 5 (DR5) on cancer cells to induce apoptosis. In human leukemia HL-60 cells, it increases DR5 expression, reduces Bcl-2 levels, and activates caspase-3. It also inhibits fibroblast growth factor receptor-1 (FGFR-1) signaling in endothelial cells. Siphonaxanthin suppresses the proliferation, migration, and tubular formation of human umbilical vein endothelial cells (HUVECs), as well as the growth of microvessels in rat aorta rings. Additionally, it has anti-inflammatory properties by blocking the translocation of high-affinity IgE receptors (FcεRI) to lipid rafts in mast cells. Siphonaxanthin shows potential for research into diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis.Formule :C40H56O4Couleur et forme :SolidMasse moléculaire :600.87VEGFR-2-IN-16
VEGFR-2-IN-16 (Compound 15b) is a potent inhibitor of VEGFR-2 (IC50: 86.36 nM) that exhibits antitumour effects.Formule :C21H13Cl2N3O2Couleur et forme :SolidMasse moléculaire :410.25PF-06263276
CAS :PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63EGFR-IN-161
CAS :EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.Formule :C33H36Cl2N8O2Couleur et forme :SolidMasse moléculaire :647.597MM-589 TFA
CAS :MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formule :C30H45F3N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :686.72W23-1006
CAS :W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Formule :C17H12BrN3O5Couleur et forme :SolidMasse moléculaire :418.198EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23Protein kinase inhibitor 11
CAS :Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.Formule :C21H18FN5O2SCouleur et forme :SolidMasse moléculaire :423.463JP-153
CAS :JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.Formule :C21H19NO5Couleur et forme :SolidMasse moléculaire :365.379Dual Cathepsin L/JAK-IN-1
CAS :DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formule :C19H18ClN5Couleur et forme :SolidMasse moléculaire :351.833Protein kinase inhibitor 10
CAS :Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.Formule :C14H9FN6S2Couleur et forme :SolidMasse moléculaire :344.39HER2-IN-21
CAS :HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447VEGFR/PDGFR-IN-1
CAS :VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.Formule :C17H21N5O3Couleur et forme :SolidMasse moléculaire :343.38Fanregratinib
CAS :Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.Formule :C27H33ClN6O2Couleur et forme :SolidMasse moléculaire :509.04TZEP7
CAS :TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.Formule :C27H19ClFNSCouleur et forme :SolidMasse moléculaire :443.963FGFR1 inhibitor-17
CAS :FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.Formule :C16H13ClN2O3Couleur et forme :SolidMasse moléculaire :316.739TrxR/EGFR-IN-1
CAS :TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Formule :C24H24AuClFN6O2PCouleur et forme :SolidMasse moléculaire :710.878SJ-C1044
CAS :SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.Formule :C25H14F7N7OCouleur et forme :SolidMasse moléculaire :561.41Tyrosine kinase-IN-9
CAS :Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.Formule :C20H14ClN3O3Couleur et forme :SolidMasse moléculaire :379.796TGF-βRI inhibitor 3
CAS :TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.396lirucitinib
CAS :Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468EGFR-IN-133
CAS :EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.Formule :C27H29F2N7O3Couleur et forme :SolidMasse moléculaire :537.56FGFR-IN-16
CAS :FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.Formule :C30H27Cl2N7O4Couleur et forme :SolidMasse moléculaire :620.49Tesevatinib tosylate
CAS :Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59HSN748
CAS :HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.Formule :C27H24F3N7OCouleur et forme :SolidMasse moléculaire :519.521FAK-IN-23
CAS :FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).Formule :C32H38F3N5O8Couleur et forme :SolidMasse moléculaire :677.668Oxamic acid
CAS :Oxamic acid is an LDHA inhibitor, antitumor, induces apoptosis, downregulates EGFR expression, and inhibits cancer stem cell properties and EMT.Formule :C2H3NO3Couleur et forme :SolidMasse moléculaire :89.05WS-11
CAS :WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formule :C26H22FN9O2Couleur et forme :SolidMasse moléculaire :511.51BPI-15086
CAS :BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formule :C29H33ClN8O4Couleur et forme :SolidMasse moléculaire :593.08Si306
CAS :Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formule :C25H26BrClN6OSCouleur et forme :SolidMasse moléculaire :573.94Cernuumolide J
CAS :Cernuumolide J (TMJ-105) functions as a JAK2/STAT3 inhibitor and exhibits potent activity against HEL leukemia cells by inhibiting their growth in both time-dependent and concentration-dependent manners, with an IC 50 value of 1.79 μM. This compound effectively induces G2/M phase arrest and apoptosis by downregulating the phosphorylation of JAK2, STAT3, and Erk, while simultaneously upregulating the phosphorylation of JNK and p38 MAPK. Cernuumolide J holds potential for research applications in anti-cancer therapy.Formule :C24H34O8Couleur et forme :SolidMasse moléculaire :450.52FAK inhibitor 7
CAS :FAK inhibitor7, a potent FAK inhibitor, demonstrates an IC50 of 3.58 nM. This compound effectively inhibits downstream signaling cascades of FAK (such as Src and AKT), which leads to cell cycle arrest at the G0/G1 phase and induces cytotoxic autophagy in ovarian cancer cells. Additionally, FAK inhibitor7 has been shown to suppress tumor metastasis and growth in ovarian cancer mouse models.Formule :C32H37N7O3Couleur et forme :SolidMasse moléculaire :567.68Vecabrutinib
CAS :Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.Formule :C22H24ClF4N7O2Degré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :529.92Ref: TM-T17220
1mg82,00€5mg177,00€10mg289,00€25mg470,00€50mg623,00€100mg874,00€1mL*10mM (DMSO)207,00€Vatalanib hydrochloride
CAS :Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Formule :C20H16Cl2N4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :383.27Zotizalkib
CAS :TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formule :C21H20F3N5O3Degré de pureté :98.7%Couleur et forme :SolidMasse moléculaire :447.41Ref: TM-T9414
1mg114,00€5mg268,00€10mg439,00€25mg879,00€50mg1.395,00€100mg1.873,00€1mL*10mM (DMSO)303,00€NDI-034858
CAS :NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFormule :C23H24N8O3Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :460.49JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63JAK2-IN-7
CAS :JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formule :C26H33N7ODegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :459.59Ref: TM-T35900
1mg138,00€5mg334,00€10mg597,00€25mg1.234,00€50mg1.648,00€100mg2.232,00€1mL*10mM (DMSO)339,00€XMD-17-51 Trifluoroacetate
CAS :XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Formule :C23H25F3N8O3Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :518.49Ibrutinib Racemate
CAS :Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.5Imbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Couleur et forme :Odour LiquidHMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Couleur et forme :Odour LiquidTLC9995-0188
CAS :Tyrosine-protein kinase ABL, IC50: 1500 nMFormule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37ENMD-2076 tartrate
CAS :ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Formule :C25H31N7O6Couleur et forme :SolidMasse moléculaire :525.56PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Couleur et forme :Odour LiquidDihydrodiol-Ibrutinib
CAS :PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formule :C25H26N6O4Couleur et forme :SolidMasse moléculaire :474.521XMU-MP-3
CAS :XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Formule :C27H27F3N8OCouleur et forme :SolidMasse moléculaire :536.563Nimotuzumab (powder)
CAS :Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Couleur et forme :LiquidDesidustat
CAS :Desidustat is an inhibitor of HIF hydroxylase.
Formule :C16H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :332.31Ref: TM-T5176
Produit arrêtéOlmutinib
CAS :Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormule :C26H26N6O2SDegré de pureté :99.14%Couleur et forme :SolidMasse moléculaire :486.59Duligotuzumab
CAS :Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Degré de pureté :95%Couleur et forme :Liquid3,3',4,4'-Tetrabromobiphenyl
CAS :Produit contrôléApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Formule :C12H6Br4Couleur et forme :Off-White To Light BrownMasse moléculaire :469.79VEGFR-IN-1
CAS :VEGFR inhibitorFormule :C19H16ClN3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :337.8
